Urokinase and Dornase alfa

Protein / enzyme

Urokinase and Dornase alfa is one of 3 small molecule programs targeting Pleural Empyema. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pleural EmpyemaActive, not recruiting

Pleural EmpyemaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Pleural Empyema

#DrugCompanyPhaseTrials

Activase

Urokinase

1 3

Urokinase and Dornase alfa

AAzienda Ospedaliera di Padova

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pleural Empyema1 trial

Dornase Alfa and Urokinase for Kids With Pleural Empyema

Unknown status·AAzienda Ospedaliera di Padova·Phase 2/3·NCT00502632·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Urokinase and Dornase alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Urokinase and Dornase alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Urokinase and Dornase alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Azienda Ospedaliera di Padova company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Company: AAzienda Ospedaliera di Padova

Urokinase and Dornase alfa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pleural Empyema1 trial

References

Drug Info

Quick Facts

Related News